|
non-small cell lung cancer |
16 |
|
lung cancer |
11 |
|
targeted therapy |
11 |
|
radiotherapy |
10 |
|
bintrafusp alfa |
8 |
|
correlative biomarkers |
8 |
|
efficacy |
8 |
|
recurrent or metastatic nasopharyngeal cancer |
8 |
|
safety |
8 |
|
breast cancer |
7 |
|
immunotherapy |
6 |
|
non-small-cell lung cancer |
6 |
|
nsclc |
6 |
|
overall survival |
6 |
|
brain metastasis |
5 |
|
chemotherapy |
5 |
|
deep learning |
5 |
|
lymphopenia |
5 |
|
radiomics |
5 |
|
biomarker |
4 |
|
cancer management |
4 |
|
checkpoint inhibitor |
4 |
|
chinese medicine |
4 |
|
hcc |
4 |
|
hepatocellular carcinoma |
4 |
|
herbal medicine |
4 |
|
radiation esophagitis |
4 |
|
radiation pneumonitis |
4 |
|
sbrt |
4 |
|
stereotactic ablative radiation therapy |
4 |
|
stereotactic body radiation therapy (sbrt) |
4 |
|
stereotactic body radiotherapy |
4 |
|
stereotactic radiation therapy |
4 |
|
survival |
4 |
|
systemic tumor immune environment |
4 |
|
traditional chinese medicine |
4 |
|
tumor immune microenvironment |
4 |
|
ventilation |
4 |
|
biomarkers |
3 |
|
cytokine |
3 |
|
functional imaging |
3 |
|
immune biomarkers |
3 |
|
immune checkpoint inhibitors |
3 |
|
low-dose volume |
3 |
|
pneumonitis |
3 |
|
prediction model |
3 |
|
prognosis |
3 |
|
radiation |
3 |
|
radiation therapy |
3 |
|
radiosensitivity |
3 |
|
radiotherapy (rt) |
3 |
|
risk factors |
3 |
|
small cell lung cancer |
3 |
|
stereotactic body radiation therapy |
3 |
|
4dct |
2 |
|
acupuncture |
2 |
|
bone suppression |
2 |
|
brachial plexopathy |
2 |
|
brachial plexus |
2 |
|
cancer related symptoms |
2 |
|
cervical cancer |
2 |
|
computed tomography |
2 |
|
conditional survival |
2 |
|
coronavirus disease 2019 (covid-19) |
2 |
|
deformable image registration |
2 |
|
delineation |
2 |
|
dose |
2 |
|
elective nodal irradiation |
2 |
|
integrin αvβ3 |
2 |
|
lung |
2 |
|
lung dosimetric factors |
2 |
|
lymph node tumor |
2 |
|
meta-analysis |
2 |
|
metabolic tumor volume |
2 |
|
n stage |
2 |
|
nasopharyngeal carcinoma |
2 |
|
non-small cell lung cancer (nsclc) |
2 |
|
nonsmall-cell lung cancer |
2 |
|
non–small cell lung cancer |
2 |
|
normal tissue complication probability |
2 |
|
ntcp |
2 |
|
palliative care |
2 |
|
pet imaging |
2 |
|
plasma |
2 |
|
positron emission tomography/computed tomography |
2 |
|
proteomics |
2 |
|
quality of life |
2 |
|
radiation pneumonitis (rp) |
2 |
|
radiation techniques |
2 |
|
radiation-induced lung fibrosis |
2 |
|
radiation-induced lung toxicity |
2 |
|
randomized controlled trial |
2 |
|
sabr |
2 |
|
serum |
2 |
|
single-cell transcriptomics |
2 |
|
small-cell lung cancer |
2 |
|
soluble programmed death ligand 1 |
2 |
|
support vector machine |
2 |
|
surgery |
2 |
|
systemic tumor immune environment (stie) |
2 |
|
toxicity |
2 |
|
tumor geometry |
2 |
|
tumor immune microenvironment (time) |
2 |
|
tumor marker |
2 |
|
18 f-fdg pet |
1 |
|
18 f-rgd pet/ct |
1 |
|
18 fdg-pet |
1 |
|
18f-rgd |
1 |
|
3-dimensional conformal radiotherapy |
1 |
|
3d conformal radiation |
1 |
|
3d conformal radiation therapy |
1 |
|
4d-mri |
1 |
|
5d-mri |
1 |
|
[ f]2-fluoro-2-deoxyglucose 18 |
1 |
|
abemaciclib |
1 |
|
ablative radiation |
1 |
|
accelerated irradiation |
1 |
|
accelerated proliferation |
1 |
|
acquired resistance |
1 |
|
acr |
1 |
|
adaptive radiation therapy |
1 |
|
adaptive radiotherapy (art) |
1 |
|
adaptive therapy |
1 |
|
adaptive treatment planning |
1 |
|
adjuvant |
1 |
|
adjuvant therapy |
1 |
|
adult |
1 |
|
adverse events |
1 |
|
aged |
1 |
|
amino acid blood level |
1 |
|
anal canal cancer |
1 |
|
anal cancer |
1 |
|
anlotinib |
1 |
|
antiangiogenic |
1 |
|
antiangiogenic therapy |
1 |
|
appropriateness criteria |
1 |
|
artificial intelligence |
1 |
|
asbestos |
1 |
|
atlas |
1 |
|
axillary lymph nodes |
1 |
|
bayesian network analysis |
1 |
|
bayesian statistics |
1 |
|
biomarker study |
1 |
|
biophysical interactions |
1 |
|
bladder volume |
1 |
|
boost |
1 |
|
brachytherapy |
1 |
|
brain metastases |
1 |
|
brain radiotherapy |
1 |
|
cancer chemotherapy |
1 |
|
cancer staging |
1 |
|
carcinoma |
1 |
|
central |
1 |
|
chemoradiation |
1 |
|
chemoradiotherapy |
1 |
|
chest radiograph |
1 |
|
chest radiography |
1 |
|
chest x-ray (cxr) |
1 |
|
china |
1 |
|
circulating immune cells |
1 |
|
cisplatin |
1 |
|
classification |
1 |
|
clinical target volume margin |
1 |
|
clinical trials |
1 |
|
complications |
1 |
|
concurrent chemotherapy |
1 |
|
cone-beam ct (cbct) |
1 |
|
constrained lasso |
1 |
|
contouring |
1 |
|
conventional fractionation radiotherapy (crt) |
1 |
|
conventionally fractionated radiotherapy |
1 |
|
cox2 |
1 |
|
crt |
1 |
|
ct |
1 |
|
ct scan |
1 |
|
ct-to-perfusion translation |
1 |
|
cytokines |
1 |
|
cytotoxic t lymphocyte |
1 |
|
d-1mt |
1 |
|
definitive chemoradiotherapy |
1 |
|
definitive radiotherapy |
1 |
|
dfh |
1 |
|
digestive system cancers |
1 |
|
disease progression |
1 |
|
dismetric analysis |
1 |
|
dna repair pathway genes |
1 |
|
dose distributions |
1 |
|
dose escalation |
1 |
|
dose finding |
1 |
|
dose response curve |
1 |
|
dose survival model |
1 |
|
dose tolerance |
1 |
|
dosimetric analysis |
1 |
|
dosimetric parameters |
1 |
|
doubling time |
1 |
|
drug resistance |
1 |
|
dvh |
1 |
|
early diagnosis |
1 |
|
early onset of severe lymphopenia |
1 |
|
early stage non-small cell lung cancer |
1 |
|
early-stage non-small-cell lung cancer |
1 |
|
edic |
1 |
|
effective dose to the circulating immune cells (edic) |
1 |
|
efficacy toxicity trade-off |
1 |
|
egfr mutation |
1 |
|
egfr-tki |
1 |
|
elderly |
1 |
|
epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tkis) |
1 |
|
epidermal growth factor receptor tyrosine kinase inhibitors (egfr-tkis) |
1 |
|
epidermal growth factor receptor-tyrosine kinase inhibitor (egfr-tki) |
1 |
|
ercc1 and ercc2 |
1 |
|
esophageal cancer |
1 |
|
esophageal carcinoma |
1 |
|
esophageal squamous cell carcinoma |
1 |
|
esophagitis |
1 |
|
esophagus |
1 |
|
excision cavity |
1 |
|
experimental colitis |
1 |
|
facilities |
1 |
|
faza |
1 |
|
fdg pet |
1 |
|
fdg-pet |
1 |
|
fetnim |
1 |
|
fgf3/4/19/ccnd1 amplification |
1 |
|
fibrosis |
1 |
|
film dosimetry |
1 |
|
flash radiotherapy |
1 |
|
fmiso |
1 |
|
functional lung avoidance radiation therapy |
1 |
|
gastric cancer |
1 |
|
gefitinib resistance |
1 |
|
gene mutation |
1 |
|
grid therapy |
1 |
|
gross tumor volume |
1 |
|
ground glass nodule |
1 |
|
growth factors |
1 |
|
heart dose |
1 |
|
high dose |
1 |
|
histology |
1 |
|
hyperfractionated accelerated irradiation |
1 |
|
hyperfractionated irradiation |
1 |
|
hypo-fractionation |
1 |
|
hypofraction |
1 |
|
hypofractionated radiotherapy |
1 |
|
hypoxia |
1 |
|
ido1 |
1 |
|
immune organ at risk |
1 |
|
immune system |
1 |
|
immune-response |
1 |
|
immunomodulatory |
1 |
|
immunosuppressive |
1 |
|
incidental dose |
1 |
|
incidental nodal irradiation |
1 |
|
incomplete resection |
1 |
|
inoperable |
1 |
|
intensity modulated radiotherapy (imrt) |
1 |
|
intensity-modulated radiation therapy (imrt) |
1 |
|
interfraction motion |
1 |
|
internal mammary nodes |
1 |
|
intestinal myofibroblast |
1 |
|
intrafraction motion |
1 |
|
invasive thymoma |
1 |
|
involved-field irradiation |
1 |
|
isolated nodal failure |
1 |
|
joint prediction of lc and rp2 |
1 |
|
lewis rats |
1 |
|
limited-stage sclc |
1 |
|
limited-stage small-cell lung cancer (sclc) |
1 |
|
liquid biopsy |
1 |
|
local control |
1 |
|
locoregional surveillance |
1 |
|
long-term outcomes |
1 |
|
loss of heterozygosity |
1 |
|
low-dose radiotherapy |
1 |
|
ls-sclc |
1 |
|
lung carcinoma |
1 |
|
lung damage |
1 |
|
lung injury |
1 |
|
lung metastasis |
1 |
|
lung neoplasm |
1 |
|
lung neoplasms |
1 |
|
lung toxicity |
1 |
|
ly2874455 |
1 |
|
lymph node metastasis |
1 |
|
lymphocyte count |
1 |
|
lymphocyte nadir |
1 |
|
m6p/igf2r |
1 |
|
machine learning |
1 |
|
magnetic resonance imaging (mri) |
1 |
|
malignancies |
1 |
|
malignant pleural mesothelioma |
1 |
|
mannose 6-phosphate/insulin-like growth factor type 2 receptor |
1 |
|
mean body dose |
1 |
|
mean lung dose |
1 |
|
mediastinal lymph node |
1 |
|
mediastinal tumor |
1 |
|
medical operability |
1 |
|
medically inoperable |
1 |
|
metastasis |
1 |
|
microscopic extension |
1 |
|
mid-treatment |
1 |
|
molecular subtype |
1 |
|
monte carlo-based treatment planning |
1 |
|
mr-guided radiotherapy |
1 |
|
multi-contrast mri |
1 |
|
multi-modality therapy |
1 |
|
multidisciplinary care |
1 |
|
multiobjective bayesian networks |
1 |
|
mutation |
1 |
|
nasopharyngeal (npc) |
1 |
|
nasopharyngeal cancer |
1 |
|
national comprehensive cancer network (nccn) |
1 |
|
nccn clinical practice guidelines |
1 |
|
nccn guidelines |
1 |
|
negative predictive value |
1 |
|
neoadjuvant chemoradiotherapy |
1 |
|
neoadjuvant chemotherapy |
1 |
|
nf-κb |
1 |
|
node-negative disease |
1 |
|
nodes |
1 |
|
nomogram |
1 |
|
non-small cell |
1 |
|
non-small cell lung |
1 |
|
nonsmall cell lung caner |
1 |
|
normal tissue complication probability (ntcp) |
1 |
|
normal tissue toxicity |
1 |
|
nox5 |
1 |
|
objective response rate (orr) |
1 |
|
oligometastases |
1 |
|
operable |
1 |
|
optimal treatment regime |
1 |
|
overall survival (os) |
1 |
|
palliation |
1 |
|
pancoast tumor |
1 |
|
parameters |
1 |
|
patient decision aid |
1 |
|
pci |
1 |
|
pd-1 immune checkpoint inhibition |
1 |
|
performance status |
1 |
|
perfusion |
1 |
|
perfusion imaging |
1 |
|
pericardial dose |
1 |
|
pericardial effusion |
1 |
|
personalized medicine |
1 |
|
personalized radiation therapy |
1 |
|
personalized radiotherapy |
1 |
|
pet |
1 |
|
pet/ct |
1 |
|
ph domain leucine-rich-repeats protein phosphatase (phlpp) |
1 |
|
phase i |
1 |
|
planning study |
1 |
|
plasma egfr thr790met (t790m) |
1 |
|
platelet |
1 |
|
platelet factor 4 (pf4) |
1 |
|
platelet-to-lymphocyte ratio |
1 |
|
pleural effusion |
1 |
|
poor risk |
1 |
|
positron emission tomography |
1 |
|
positron emission tomography (pet) |
1 |
|
postoperative therapy |
1 |
|
postresection recurrence |
1 |
|
precision medicine |
1 |
|
predictive model |
1 |
|
predictor |
1 |
|
probability density function |
1 |
|
pulmonary function tests |
1 |
|
q-spect |
1 |
|
qa |
1 |
|
quality |
1 |
|
quality assurance |
1 |
|
quality of life (qol) |
1 |
|
quantec |
1 |
|
quantitative ct analysis |
1 |
|
radiation break |
1 |
|
radiation complications |
1 |
|
radiation dose |
1 |
|
radiation dose to the blood |
1 |
|
radiation esophagitis (re) |
1 |
|
radiation induced immune toxicity |
1 |
|
radiation induced pleural effusion |
1 |
|
radiation injuries |
1 |
|
radiation injury |
1 |
|
radiation oncology |
1 |
|
radiation therapy (rt) |
1 |
|
radiation-induced immune toxicity |
1 |
|
radiobiology |
1 |
|
radiofrequency ablation (rfa) |
1 |
|
radioimmunotherapy |
1 |
|
radiotherapy dose |
1 |
|
radiotherapy planning |
1 |
|
re-irradiation |
1 |
|
reactive oxygen species |
1 |
|
real-world practice |
1 |
|
regorafenib |
1 |
|
replanning |
1 |
|
reproducibility |
1 |
|
resection |
1 |
|
respiratory motion |
1 |
|
response-adapted radiotherapy |
1 |
|
risk factor |
1 |
|
s1 |
1 |
|
salvage esophagectomy |
1 |
|
setup uncertainty |
1 |
|
shared decision making |
1 |
|
single nuclear polymorphism |
1 |
|
single nucleotide polymorphism |
1 |
|
single photon emission computerized tomography |
1 |
|
single-nucleotide-polymorphisms (snps) |
1 |
|
single-photon emission computerized tomography |
1 |
|
smac mimetic |
1 |
|
snp |
1 |
|
spatially fractionated radiotherapy |
1 |
|
spinal cord |
1 |
|
stage iii |
1 |
|
stage iiia |
1 |
|
standard uptake value (suv) |
1 |
|
standardized uptake value |
1 |
|
statistical uncertainties |
1 |
|
stenting |
1 |
|
stereotactic ablative body radiotherapy (sabr) |
1 |
|
stereotactic ablative radiotherapy |
1 |
|
stereotactic body ablative radiotherapy |
1 |
|
stereotactic body radiotherapy (sbrt) |
1 |
|
stereotactic radiosurgery |
1 |
|
super-resolution |
1 |
|
super-voxel |
1 |
|
superior vena cava syndrome (svc syndrome, svcs) |
1 |
|
surgical scar |
1 |
|
systematic review |
1 |
|
target volume delineation |
1 |
|
target volumes |
1 |
|
tgf-β1 |
1 |
|
thoracic |
1 |
|
thoracic malignancies |
1 |
|
thoracic radiotherapy |
1 |
|
three-dimensional conformal radiation therapy |
1 |
|
threshold |
1 |
|
thrombomodulin |
1 |
|
thymic carcinoma |
1 |
|
thymoma |
1 |
|
time to treatment |
1 |
|
tnfα |
1 |
|
transforming growth factor |
1 |
|
transforming growth factor beta |
1 |
|
transforming growth factor β |
1 |
|
transforming growth factor β1 |
1 |
|
transforming growth factor β1 (tgfβ1) |
1 |
|
transforming growth factor-β |
1 |
|
treatment delay |
1 |
|
treatment planning |
1 |
|
treatment response |
1 |
|
treatments |
1 |
|
tumor board |
1 |
|
tumor cell density |
1 |
|
tumor control |
1 |
|
tumor control probability (tcp) |
1 |
|
tumor control probability modeling |
1 |
|
tumor regression |
1 |
|
tumor suppressor |
1 |
|
tumor-enhanced contrast |
1 |
|
uncertainty volume histograms |
1 |
|
utilities |
1 |
|
utility |
1 |
|
waiting time |
1 |
